All anti-tumor restoring effects of PI3K inhibitors strongly suggest that small pharmacological inhibitors that target PI3Kγ or δ isoforms or all isoforms together can be a suitable powerful combinatorial partner to enhance the antitumor efficacy of ENO1 vaccination (Figure 4). This evidence concerns the gene PIK3CD and neoplasm.